Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
Daniel Y.C. Heng, MD, MPH, FRCPC
Advertisement
Articles by Daniel Y.C. Heng, MD, MPH, FRCPC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
2
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
3
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5